Fathimanoud, Correspondent, India Pharma Outlook
Global pharma companies outsource to India because the country offers a differentiated mix of scientific talent, cost competitiveness, regulatory familiarity, and expanding infrastructure for complex work.
The China+1 strategy opened the door, yet companies now look beyond simple risk mitigation. They seek partners that can contribute across the full drug development journey.
Indian CDMOs already move beyond a model defined mainly by cost and manufacturing scale.
The next phase depends on how effectively these firms contribute scientific insight, anticipate challenges, and help clients make better decisions earlier.
Facilities now handle advanced chemical synthesis, continuous manufacturing, and integrated development services that earlier generations of Indian plants did not offer.
Tier-1 Indian CDMOs operate with embedded quality systems and clean regulatory track records. Global clients conducting audits increasingly recognize this strength. At the same time, the industry still faces a consistency challenge across the broader ecosystem.
Companies that invest deliberately in capability, business-model evolution and shared risk with clients stand to convert short-term diversification wins into durable strategic partnerships.
“Supply chain rebalancing initiatives have benefitted players in the CDMO space at a broader market level, and the companies will continue to benefit from long-term client contracts and investments into newer modalities—peptides, antibody drug conjugates, and oligonucleotides, said Nishith Sanghvi, Director, India Ratings & Research.
Key reasons companies choose India CDMOs include:
India does not need to copy China’s volume-driven model. Its opportunity lies in pairing established strengths with higher-value services that global innovators need most.
Also Read: Why India's Pharma Manufacturing Boom Needs More Women in Core Plant Operations
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")